When was Adlai Nortye founded?

Adlai Nortye was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is Adlai Nortye located?

Adlai Nortye is headquartered in Hangzhou, China. It is registered at North Brunswick, New Jersey.

Who is the current CEO of Adlai Nortye?

Carsten Lu of Adlai Nortye. They have also founded 1 company.

How many employees does Adlai Nortye have?

As of Jun 30, 2026, the latest employee count at Adlai Nortye is 65.

Is Adlai Nortye a funded company?

Adlai Nortye is a funded company, having raised a total of $253M across 4 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jun 27, 2018.

When was the latest funding round of Adlai Nortye?

Adlai Nortye's latest funding was a $***** Post IPO round on Apr 16, 2026, with participation from 5 investors.

Where does Adlai Nortye rank among its competitors?

Adlai Nortye ranks 150th amongst 3282 active competitors, of which 1120 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Adlai Nortye?

Adlai Nortye's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Adlai Nortye - 2026 Company Profile, Team, Funding & Competitors

Adlai Nortye is a public company based in Hangzhou (China), founded in 2014 by Carsten Lu. It operates as a Developer of immune oncolytic therapies for treating cancer. Adlai Nortye has raised $253M in funding from investors like Tigermed, Matrix Partners China and SDIC. The company has 3282 active competitors, including 1120 funded and 777 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of immune oncolytic therapies for treating cancer. The company's lead product, REOLYSIN is used for treating breast cancer. It selectively lyses tumors and activates the innate and adaptive immune systems. Other candidates of the company include AN0025 (for solid tumors), AN0015 & AN3005 (for multiple tumors).

Website: www.adlainortye.com
Email ID: *****@adlainortye.com
Phone Number: +86 **********
Registered Address: North Brunswick, New Jersey

Key Metrics

Founded Year

2014

Location

Hangzhou, China

Stage

Public

Total Funding

$253M in 4 rounds

Latest Funding Round

Post IPO, Apr 16, 2026, $*****

Investors

Tigermed & 21 more

Ranked

150^th among 3282 active competitors

Employee Count

65 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3003 more

Exit Details

Public

View Adlai Nortye's full profile

Adlai Nortye is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADLAI NORTYE USA INC CIN: 823486391 , United States, Active		-	19 (As on Dec 31, 2024)	-

Adlai Nortye got listed on Sep 29, 2023.

Click here to take a look at Adlai Nortye's IPO in detail

Adlai Nortye has raised a total funding of $253M over 4 rounds. Its first funding round was on Jun 27, 2018. Its latest funding round was a Post IPO round on Apr 16, 2026 for $*****. 5 investors participated in its latest round. Adlai Nortye has 22 institutional investors.

Here is the list of recent funding rounds of Adlai Nortye:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 16, 2026	6598610	Post IPO	2952590	2941998	8094636	8075402
Jul 15, 2021	7877222	Series D	7771859	8656775	5218071	Triwise Capital & 5 more
Aug 04, 2020	1677304	Series C	5213576	4522021	Tigermed & 1 more	IcbcAmg

Access funding benchmarks and valuations. Sign up today!

View details of Adlai Nortye's funding rounds and investors

The founders of Adlai Nortye is Carsten Lu.

Here are the details of Adlai Nortye's key team members:

Carsten Lu: Founder & ceo of Adlai Nortye.

View details of Adlai Nortye's Founder profiles and Board Members

Adlai Nortye's employee count trend

Adlai Nortye has 65 employees as of Jun 26. Here is Adlai Nortye's employee count trend over the years:

Uncover Adlai Nortye's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adlai Nortye include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Adlai Nortye, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
150th	Adlai Nortye 2014, Hangzhou (China), Public	Developer of immune oncolytic therapies for treating cancer	$253M	Perceptive Advisors, Soleus Capital & 20 others	61/100